Quantbot Technologies LP Decreases Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Quantbot Technologies LP cut its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 95.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,026 shares of the specialty pharmaceutical company’s stock after selling 21,601 shares during the quarter. Quantbot Technologies LP’s holdings in Supernus Pharmaceuticals were worth $32,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of SUPN. Segall Bryant & Hamill LLC acquired a new position in Supernus Pharmaceuticals in the 3rd quarter worth approximately $791,000. Renaissance Technologies LLC lifted its position in Supernus Pharmaceuticals by 26.4% during the second quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company’s stock valued at $45,077,000 after purchasing an additional 351,900 shares during the period. Bank of Montreal Can boosted its holdings in Supernus Pharmaceuticals by 1,508.0% in the second quarter. Bank of Montreal Can now owns 116,322 shares of the specialty pharmaceutical company’s stock valued at $3,287,000 after purchasing an additional 109,088 shares during the last quarter. Candriam S.C.A. acquired a new stake in Supernus Pharmaceuticals during the 2nd quarter worth about $3,795,000. Finally, Stephens Investment Management Group LLC raised its stake in shares of Supernus Pharmaceuticals by 1.8% during the 3rd quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company’s stock valued at $60,246,000 after buying an additional 33,710 shares during the last quarter.

Supernus Pharmaceuticals Stock Performance

SUPN opened at $37.17 on Friday. The company has a fifty day moving average of $34.84 and a two-hundred day moving average of $31.63. The stock has a market capitalization of $2.05 billion, a price-to-earnings ratio of 34.74 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $39.37.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.25. The firm had revenue of $175.70 million during the quarter, compared to analyst estimates of $157.35 million. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. Supernus Pharmaceuticals’s revenue for the quarter was up 14.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.29) EPS. On average, equities research analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Cowen restated a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Piper Sandler restated a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Insider Transactions at Supernus Pharmaceuticals

In related news, Director Georges Gemayel sold 14,213 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $36.62, for a total transaction of $520,480.06. Following the completion of the transaction, the director now owns 13,315 shares in the company, valued at $487,595.30. This represents a 51.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Frank Mottola sold 15,000 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $36.98, for a total value of $554,700.00. Following the completion of the sale, the senior vice president now owns 8,200 shares in the company, valued at approximately $303,236. The trade was a 64.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 154,213 shares of company stock valued at $5,660,180 in the last three months. 9.30% of the stock is currently owned by company insiders.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.